Brief: Sio Gene Therapies Says On-Track To Report Topline Results From Low-Dose Cohort By End Of 2020
02/12/2020 12:35
Dec 2 (Reuters) - Sio Gene Therapies Inc SIOX.O :
* SIO GENE THERAPIES ANNOUNCES FIRST PATIENT DOSED IN
HIGH-DOSE
COHORT OF AXO-AAV-GM1 CLINICAL TRIAL IN PATIENTS WITH GM1
GANGLIOSIDOSIS
* SIO GENE THERAPIES INC - ON-TRACK TO REPORT TOPLINE
RESULTS FROM
LOW-DOSE COHORT BY END OF 2020
Source text for Eikon: ID:nGNX3bPp1T
Further company coverage: SIOX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Sio Gene Therapies
See all newsBrief: Sio Gene Therapies Inc - On March 14, Got Notice That Nasdaq Has Determined That Company's Common Stock Will Be Delisted From Nasdaq Capital Market
Brief: Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Brief: Sio Gene Therapies Inc. Announces Board Approval Of Plan Of Complete Liquidation, Dissolution
Brief: Sio Gene Therapies Announces Second Quarter Financial Results
Brief: Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results